Asia trades mixed with COVID vaccination in focus
Equities on major stock markets in the Asia-Pacific region were mixed on Monday as investors mainly focus on vaccination against COVID-19 and the economic recovery from the virus-caused crisis.
Over the weekend, Russia approved its third coronavirus jab, granting an emergency use authorization for CoviVac developed by the Chumakov Federal Scientific Center. On the other hand, Vector Institute’s EpiVacCorona provides one year of immunity against the virus, according to the institute’s head Rinat Maksyuto.
The Nikkei 225 added 0.60% at 4:50 am CET, while the Hang Seng and the Kospi gained 0.45% and 0.14% at the same time, respectively. The Shenzhen Composite plunged 1.33% at 4:45 am CET, the Shanghai Composite slid 0.06% at 4:30 am CET, and the S&P/ASX 200 in Australia lost 0.08% at 4:52 am CET. The dollar rose 0.17% against the greenback, changing hands for 105.6390 a minute later.
Get involved!
Comments